LSE Health

🌍✨ New Research Highlight! 'Cultural Persistence of Self-Assessed Health: A Study of First- and Second-Generation Migrants'✨🌍 Ever wondered how cultural attitudes shape how we view our health? 🩺💭 This latest study from Joan Costa-i-Font (he/him) and colleagues explores cultural persistence in health self-assessments among first- and second-generation migrants across Europe. 🔍 Key Insights: ✅ Migrants’ self-reported health aligns closely with perceptions from their home country—showing a 0.17 standard deviation correlation per standard deviation change in the sending country. ✅ This connection varies by age and persists even after accounting for factors like migration timing and citizenship. ✅ Our robust analysis, spanning 90+ sending countries and 30+ European hosts, highlights the enduring influence of cultural reference points. 🤔 Why does this matter? Cross-country health comparisons aren't just about objective measures—they also reflect the cultural lens through which people view their health. 🌐 Understanding these dynamics can refine global health policies and enhance our interpretation of self-reported data. Read the article in full https://lnkd.in/ea_k6TB9 #CulturalPersistence #HealthPerception #MigrationResearch #PublicHealth #GlobalInsights

🆕 POLICY BRIEF 🆕 from the AHOPlatform on Health Systems and Policies Data digitalization promises major benefits for Africa’s health systems. Health data digitalization can empower patients, help health professionals make more informed decisions and provide the evidence needed to shape health policies. Learn more 👇 https://lnkd.in/eBGximr7 🆕 🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕 🆕 FICHE POLITIQUE 🆕 de l'AHOPlatform on Health Systems and Policies La numérisation des données promet des avantages majeurs pour les systèmes de santé en Afrique. Elle favorise l’autonomisation des patients, aide les professionnels de santé à prendre des décisions plus éclairées et fournit les preuves nécessaires pour orienter les politiques de santé. En savoir plus 👇 https://lnkd.in/eBGximr7 #PolicyBrief #AfricanHealth #DigitalHealth #AHOP

📣 Job opportunity for an Assistant Professor to join the LSE Department of Health Policy! ➡️ You will contribute to teaching on all programmes in the Department. ➡️ You will have (or will have submitted) a PhD in a relevant social science discipline by the post start date, as well as a track record or trajectory of internationally excellent, relevant publications. ➡️ You will also demonstrate the ability to teach on a range of courses relevant to health policy (e.g. health care management) currently on offer within the full-time MSc and Executive MSc programmes offered by the Department. ➡️ Excellent written and oral communication skills, including an ability to place one's specialist work within a broader social science context are also essential. ⏳ Closing date: Friday, 14 February 2025 🔗 Learn more and apply now: https://bit.ly/4fq1aP5 #LSEHealthPolicy #Hiring

Excited to be speaking on climate change and health equity at KUHS(Kerala University Of Health Sciences) on Friday - details below if you would like to join the discussion

What a year it has been for The London School of Economics and Political Science (LSE)! We are so proud to be part of this prestigious institution 📚 #2024 #LSE #HealthEconomics #HealthPolicy

The latest issue of the #LSEHealthNewsletter is out today, rounding up our research news for the end of 2024. Major features include: 👩💻 Updates from LSE Health Digital 🏥 New project to reduce childhood mortality in Zimbabwe launched by the Global Surgery Policy Unit 📖 Open call for submissions for our Special Issue of the Geneva Papers on Risks and Insurance 📉 News from the Health Inequalities Lab 🎙️ Upcoming public lectures 📑 Recent publications and blogs Read the newsletter in full here https://lnkd.in/eghCPpA6 Read past editions here https://lnkd.in/evu3av3x Signup to receive future mailouts here! https://lnkd.in/e2s7cnTD #LSEHealth #DigitalHealth #SurgicalCare #HealthEconomics #Incentives #HealthInequalities #GlobalHealth #HealthPolicy European Observatory on Health Systems and Policies AHOPlatform on Health Systems and Policies Medical Technology Research Group (MTRG) Rocco Friebel Emilie Courtin Panos Kanavos Robin van Kessel Elias Mossialos Joan Costa-i-Font (he/him) Jon Cylus Clare Wenham Olivier Wouters Nilesh Raut Stella Tsoli Pavithra Manoj Martilord Ifeanyichi, MD, MSc, PhD Maeve Sophia Bognini George Wharton

💊 More Health Lost Than Gained? Exploring #NHS Spending on New Medicines The latest study published in The Lancet reveals a critical trade-off in NHS spending: while new medicines have improved health for some, the cost has led to significant health losses elsewhere in the system. 📉 The Numbers: From 2000–2020, new drugs delivered 3.75 million years of full health at a cost of £75 billion. But if that funding had been allocated to existing NHS services, it could have generated 5 million years of full health. ⚖️ Why the Trade-Off? The NHS’s cost-effectiveness threshold for new drugs allows pharmaceutical companies to charge prices that exceed the NHS’s typical spend for the same health outcomes. This means funds are redirected from treatments and services that deliver greater value for money. 💬 What the Authors Say: ◾ Huseyin Naci The London School of Economics and Political Science (LSE): 'Innovative drugs are vital but often overpriced, forcing the NHS to make difficult trade-offs that impact other patients.' ◾ Irene Papanicolas (Brown University): 'The NHS’s tight budget magnifies the negative impact of reallocating funds to high-cost drugs.' ◾ Beth Woods (University of York): 'Pharmaceutical pricing reform is needed to ensure better health outcomes for all NHS patients.' 📢 With a recent UK government agreement committing to NICE’s cost-effectiveness threshold until 2029, this study calls for greater transparency in funding decisions and a renewed focus on equitable resource allocation. 🔗 Read the full study to understand the implications for NHS policy and population health: https://bit.ly/3ZOgjVD #HealthPolicy #PharmaceuticalPricing #NICE

📢 New research from Clare Wenham and Akhila Potluru quantifies, for the first time, the financial cost of the Intergovernmental Negotiating Body (INB) process to negotiate the pandemic agreement (previously known as the pandemic treaty). Employing a novel methodology, their study combines human resource costs, travel expenses, and event hosting costs to offer a replicable framework for evaluating the financial implications of global governance initiatives. The INB's total expenditure (in US Dollars) is estimated to be $201 million, with an additional $56 million for the parallel process of amendments to the International Health Regulations, leading to a combined governance development cost of $257 million. When this estimated financial cost of $201 million is contextualised within the broader PPR landscape, several things come to light about the INB Process: 📉 1. High Financial Costs with Opportunity Trade-offs - Although the  $201 million estimate represents only 0.63% of the average annual cost of pandemic preparedness ($31.8 billion average), the funds could have been channelled into operational health measures, such as delivering over 120 million COVID-19 vaccine doses or significantly expanding the global healthcare workforce. This raises questions about the efficiency of resource allocation. 📊 2. Inequities in Participation and Distribution - Costs and logistical challenges have disproportionately burdened low- and middle-income countries, limiting their participation in negotiations. This disparity exacerbates existing inequities, as smaller delegations often lack permanent representation in Geneva, reducing their influence on treaty outcomes. 🌎 3. Effectiveness and Strategic Challenges - Despite significant financial and political investment, the INB process has faced slow progress, limited tangible outcomes, and missed deadlines. This has arguably highlighted institutional and operational weaknesses with the process, which could hamper confidence in future multilateral or treaty efforts. Ultimately, this work opens the door for informed discussions on the cost-effectiveness of treaty-making processes in global health, and beyond. 🔗 Read the article in full https://lnkd.in/d5mAZ66Q #PandemicPreparedness #INB #GlobalHealth #TreatyMaking

📢 Registration is now open for our upcoming online lecture with Anthony McDonnell on 'Understanding the economic burden of AMR' We’ve long known that antibiotics failing due to antimicrobial resistance (AMR) could have a devastating effect on health care, and by extension this would impact the wider economy. Anthony led a recent research project for the Center for Global Development that will be the first global study to publish the national level estimates for the global burden of AMR. This was done using the latest disease burden estimates from the Institute of Health Metrics and Evaluation. CGD’s work is also the first study to model the future cost of AMR on health care systems at the national level, this study also looks at how AMR might impact tourism and hospitality. Anthony will outline the research methodology in this talk and look in detail at some of the results in discussion with LSE Health Visiting Fellow Michael Anderson and our Director, Professor Elias Mossialos. 📅 Tuesday 21 January, 6.00pm - 7.30pm GMT 🔗 Register here https://lnkd.in/eDpMvHjU 🔗 Read about our events here https://lnkd.in/e39u6GfS #AMR #HealthPolicy #HealthEconomics